01/27/2026
The FDA is shifting toward a more flexible oversight system for cell and gene therapies, which could help speed up the development of promising treatments, but also carries potential risks as the field adapts to new regulatory standards. This change reflects a balance between innovation and safety in the future of advanced therapies. Read more on this.
These could arguably be the largest changes ever to cell and gene therapy oversight in the U.S.